Merck & Co., Inc. $MRK Stock: Vise Technologies Inc. Boosts Holdings

Vise Technologies Inc. increased its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 32.8% in the third quarter, according to its most recent disclosure with the SEC. The firm owned 289,347 shares of the company’s stock after purchasing an additional 71,528 shares during the period. Vise Technologies Inc.’s holdings in Merck & Co., Inc. were worth $42,045,000 as of its most recent filing with the SEC.

Other large investors also recently made changes to their positions in the company. Investment Partners LTD. increased its holdings in Merck & Co., Inc. by 72.9% in the third quarter. Investment Partners LTD. now owns 8,813 shares of the company’s stock valued at $1,281,000 after purchasing an additional 3,715 shares during the period. BNB Wealth Management LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth approximately $210,000. Coyle Financial Counsel LLC raised its holdings in shares of Merck & Co., Inc. by 11.0% in the 3rd quarter. Coyle Financial Counsel LLC now owns 2,252 shares of the company’s stock valued at $327,000 after acquiring an additional 224 shares in the last quarter. Avestar Capital LLC boosted its holdings in shares of Merck & Co., Inc. by 3.9% in the 3rd quarter. Avestar Capital LLC now owns 19,169 shares of the company’s stock worth $2,785,000 after purchasing an additional 725 shares in the last quarter. Finally, Modera Wealth Management LLC lifted its position in Merck & Co., Inc. by 1.7% in the third quarter. Modera Wealth Management LLC now owns 48,012 shares of the company’s stock valued at $6,977,000 after purchasing an additional 821 shares during the last quarter. Institutional investors own 76.07% of the company’s stock.

Insider Activity at Merck & Co., Inc.

In other news, EVP David Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total value of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP David Williams sold 52,847 shares of the company’s stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the transaction, the executive vice president owned 31,716 shares in the company, valued at $4,084,069.32. This represents a 62.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 228,238 shares of company stock valued at $29,977,783 over the last ninety days. Corporate insiders own 0.17% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Strong Q3 results and raised outlook: Merck reported adjusted earnings of $2.49 per share versus the $2.09 analyst consensus, while revenue rose 4.7% year over year to $18.09 billion, ahead of estimates. Management raised its 2026 sales and adjusted-profit outlook, providing the main catalyst for the stock’s advance. Merck tops quarterly estimates and hikes profit outlook
• Positive Sentiment: Growth beyond Keytruda: Keytruda, including the newer Qlex formulation, delivered stronger-than-expected sales, while WINREVAIR continued to expand rapidly. Newer product launches are helping offset losses from generic competition and support Merck’s growth outlook. Merck Q3 earnings call highlights pipeline progress and raised outlook
• Positive Sentiment: Pipeline progress: Positive Phase 3 endometrial-cancer data for Keytruda and sacituzumab tirumotecan, along with FDA priority review for the latter, strengthens confidence in Merck’s oncology pipeline and its ability to address future revenue pressure. Merck Phase 3 endometrial cancer data and FDA review
• Positive Sentiment: Supportive analyst action: Guggenheim raised its price target to $171 and maintained a buy rating, indicating additional potential upside based on the earnings and pipeline outlook.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $149.75 on Friday. The company has a market cap of $369.46 billion, a PE ratio of 154.38, a price-to-earnings-growth ratio of 6.52 and a beta of 0.21. The company’s 50 day moving average is $146.90 and its 200 day moving average is $126.69. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22. Merck & Co., Inc. has a twelve month low of $82.01 and a twelve month high of $156.92.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating the consensus estimate of $2.09 by $0.40. Merck & Co., Inc. had a return on equity of 16.56% and a net margin of 3.64%. The company had revenue of $18.09 billion during the quarter, compared to analysts’ expectations of $17.33 billion. During the same period last year, the business earned $2.58 earnings per share. Merck & Co., Inc.’s quarterly revenue was up 4.7% on a year-over-year basis. On average, sell-side analysts forecast that Merck & Co., Inc. will post 2.81 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on MRK shares. Jefferies Financial Group increased their price target on shares of Merck & Co., Inc. from $152.00 to $175.00 and gave the stock a “buy” rating in a research note on Thursday, August 20th. Wolfe Research raised their price objective on shares of Merck & Co., Inc. from $155.00 to $180.00 and gave the company an “outperform” rating in a research report on Tuesday, August 25th. HSBC increased their price objective on shares of Merck & Co., Inc. from $150.00 to $172.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Rothschild & Co Redburn boosted their target price on Merck & Co., Inc. from $140.00 to $145.00 and gave the company a “buy” rating in a research report on Monday, July 6th. Finally, Wall Street Zen lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, October 3rd. Seventeen research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $156.08.

About Merck & Co., Inc.

Merck & Co, Inc is a global healthcare company that develops, manufactures and markets prescription medicines, vaccines and animal-health products. Its pharmaceutical business focuses on oncology, infectious diseases, cardiology, immunology and other areas of significant medical need. The company serves patients, healthcare providers and institutions in markets worldwide.

Merck’s principal products include Keytruda, an immunotherapy used to treat a range of cancers; Gardasil and Gardasil 9, vaccines that help protect against human papillomavirus; and Januvia and Janumet, medicines used to manage type 2 diabetes.